Impact BioMedical Announces 1-for-12.62 Reverse Stock Split Ahead of Merger
Impact BioMedical (IBO) approved an unusual reverse split to clear the path for its merger with Zoar Ltd., effective September 23, 2026.
If you own shares of Impact BioMedical Inc. (NYSE American: IBO), heads up — the company just pulled the trigger on a reverse stock split, and the ratio is oddly specific: 1 for 12.62. That means for every 12.62 shares you currently hold, you'll end up with just one share after the dust settles. The split takes effect at 12:01 a.m. Eastern Time on September 23, 2026.
So why the weird number? Reverse splits with non-round ratios are typically engineered to hit a precise share price target, often to satisfy exchange listing requirements or — in this case — to meet the conditions of an upcoming corporate deal. Impact BioMedical's board approved the move specifically to help push through its planned merger with Zoar Ltd., the company formerly known as Dr. Ashley's Ltd.
Read more NextEra and Dominion Energy Merger Could Serve 10M Customers →
If you're worried about finding your stock on the market after the split, don't panic. IBO will keep trading on the NYSE American Exchange under the same ticker symbol. The only thing changing, besides your share count, is the CUSIP number — that's the behind-the-scenes identifier brokers use to track a security. Your brokerage account should update automatically.
Reverse splits don't change the overall value of your position in theory — fewer shares at a higher price equals the same total. But in practice, they often signal that a company is navigating a specific hurdle, whether regulatory, financial, or deal-related. Here, Impact BioMedical is clearly in deal-making mode, and the split appears to be a calculated step toward closing that merger.
Continue reading at GlobalNewswire.
